DE60024442D1 - Verwendung von viralen vektoren und geladenen molekülen für die gentherapie - Google Patents

Verwendung von viralen vektoren und geladenen molekülen für die gentherapie

Info

Publication number
DE60024442D1
DE60024442D1 DE60024442T DE60024442T DE60024442D1 DE 60024442 D1 DE60024442 D1 DE 60024442D1 DE 60024442 T DE60024442 T DE 60024442T DE 60024442 T DE60024442 T DE 60024442T DE 60024442 D1 DE60024442 D1 DE 60024442D1
Authority
DE
Germany
Prior art keywords
gene therapy
viral vectors
loaded molecules
molecules
loaded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60024442T
Other languages
English (en)
Other versions
DE60024442T2 (de
Inventor
Francis Tufaro
Sonia Yeung
Brian Horsburgh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Medigene Inc
Original Assignee
University of British Columbia
Medigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Medigene Inc filed Critical University of British Columbia
Application granted granted Critical
Publication of DE60024442D1 publication Critical patent/DE60024442D1/de
Publication of DE60024442T2 publication Critical patent/DE60024442T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60024442T 1999-06-11 2000-06-12 Verwendung von viralen vektoren und geladenen molekülen für die gentherapie Expired - Fee Related DE60024442T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13887599P 1999-06-11 1999-06-11
US138875P 1999-06-11
PCT/US2000/016167 WO2000076553A1 (en) 1999-06-11 2000-06-12 Use of viral vectors and charged molecules for gene therapy

Publications (2)

Publication Number Publication Date
DE60024442D1 true DE60024442D1 (de) 2006-01-05
DE60024442T2 DE60024442T2 (de) 2006-08-03

Family

ID=22484057

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024442T Expired - Fee Related DE60024442T2 (de) 1999-06-11 2000-06-12 Verwendung von viralen vektoren und geladenen molekülen für die gentherapie

Country Status (9)

Country Link
US (1) US20040166092A1 (de)
EP (1) EP1185306B1 (de)
JP (1) JP2003501111A (de)
AT (1) ATE311205T1 (de)
AU (1) AU777120B2 (de)
CA (1) CA2376956A1 (de)
DE (1) DE60024442T2 (de)
ES (1) ES2252017T3 (de)
WO (1) WO2000076553A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1697879A (zh) * 2002-08-27 2005-11-16 安琪士多摩奇株式会社 利用病毒包膜导入生物分子的方法及其组合物和体系

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025673A1 (en) * 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US20020010144A1 (en) * 1994-04-29 2002-01-24 Robert Sobol Enhancing the sensitivity of tumor cells to therapies
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5827707A (en) * 1995-06-07 1998-10-27 Neocrin Company Method for manufacturing minimal volume capsules containing biological materials
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
EP0857217B1 (de) * 1995-10-16 2005-04-13 Dana-Farber Cancer Institute Neue expressionsvektoren und verfahren zu deren verwendung
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US6048551A (en) * 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
US6569426B2 (en) * 1997-04-03 2003-05-27 Genzyme Corporation Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity
US6248721B1 (en) * 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
WO2000015823A1 (en) * 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus
US6599909B1 (en) * 1998-09-29 2003-07-29 Uab Research Foundation Molecular chemotherapy enhancement of radiotherapy
US20050063950A1 (en) * 1998-11-19 2005-03-24 Georgetown University Systemic viral/ligand gene delivery system and gene therapy
US6602705B1 (en) * 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles

Also Published As

Publication number Publication date
EP1185306B1 (de) 2005-11-30
WO2000076553A1 (en) 2000-12-21
JP2003501111A (ja) 2003-01-14
US20040166092A1 (en) 2004-08-26
ATE311205T1 (de) 2005-12-15
EP1185306A4 (de) 2002-07-10
AU777120B2 (en) 2004-09-30
AU5608900A (en) 2001-01-02
CA2376956A1 (en) 2000-12-21
EP1185306A1 (de) 2002-03-13
DE60024442T2 (de) 2006-08-03
ES2252017T3 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
DE69637156D1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
DE69832293D1 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
DE69637147D1 (de) Transportproteine und deren verwendungen
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE69841110D1 (de) Verlängerte cdns, die für sekretierte proteine kodieren
ATE361668T1 (de) Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
EP1012603A4 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
EP1071443A4 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
AU2003273983A8 (en) Viral vectors and the use of the same for gene therapy
DK0906443T3 (da) Generering af replikerende molekyler in vivo
DE69739346D1 (de) Gereinigtes sr-p70 protein
ATE380198T1 (de) Anti-p53 spezifische einkettige- antikörperfragmente und deren verwendung
DE60024442D1 (de) Verwendung von viralen vektoren und geladenen molekülen für die gentherapie
DE60040352D1 (de) Rekombinante virale vektoren mit dem gen für den menschlichen urokinase-plasminaktivator und deren verwendung bei der behandlung von leberfibrose
DE69130845T2 (de) HLA-DR Antigen-Gen, dessen Nukleotidsequenz und Verwendung
BR9712767A (pt) Expressão especìfica para tecido de proteìna de retinoblastoma
PL374550A1 (en) Il-17 like molecules and uses thereof
DE60017924D1 (de) Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose
ATE338826T1 (de) Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression
ATE395935T1 (de) An der oberfläche von karzinomzellen lokalisiertes colligin/hsp47
ATE417066T1 (de) Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee